These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 32064896)

  • 1. Tears - more to them than meets the eye: why tears are a good source of biomarkers in Parkinson's disease.
    Edman MC; Janga SR; Kakan SS; Okamoto CT; Freire D; Feigenbaum D; Lew M; Hamm-Alvarez SF
    Biomark Med; 2020 Feb; 14(2):151-163. PubMed ID: 32064896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levels of oligomeric α-Synuclein in reflex tears distinguish Parkinson's disease patients from healthy controls.
    Hamm-Alvarez SF; Janga SR; Edman MC; Feigenbaum D; Freire D; Mack WJ; Okamoto CT; Lew MF
    Biomark Med; 2019 Dec; 13(17):1447-1457. PubMed ID: 31552762
    [No Abstract]   [Full Text] [Related]  

  • 3. Oligomeric α-synuclein is increased in basal tears of Parkinson's patients.
    Hamm-Alvarez SF; Okamoto CT; Janga SR; Feigenbaum D; Edman MC; Freire D; Shah M; Ghanshani R; Mack WJ; Lew MF
    Biomark Med; 2019 Aug; 13(11):941-952. PubMed ID: 31262201
    [No Abstract]   [Full Text] [Related]  

  • 4. Increased alpha-synuclein tear fluid levels in patients with Parkinson's disease.
    Maass F; Rikker S; Dambeck V; Warth C; Tatenhorst L; Csoti I; Schmitz M; Zerr I; Leha A; Bähr M; Lingor P
    Sci Rep; 2020 May; 10(1):8507. PubMed ID: 32444780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Pilot Study of Changes in the Level of Catecholamines and the Activity of α-2-Macroglobulin in the Tear Fluid of Patients with Parkinson's Disease and Parkinsonian Mice.
    Bogdanov V; Kim A; Nodel M; Pavlenko T; Pavlova E; Blokhin V; Chesnokova N; Ugrumov M
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33947010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oligomeric α-synuclein and β-amyloid variants as potential biomarkers for Parkinson's and Alzheimer's diseases.
    Williams SM; Schulz P; Sierks MR
    Eur J Neurosci; 2016 Jan; 43(1):3-16. PubMed ID: 26332448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated α-synuclein and NfL levels in tear fluids and decreased retinal microvascular densities in patients with Parkinson's disease.
    Lin CW; Lai TT; Chen SJ; Lin CH
    Geroscience; 2022 Jun; 44(3):1551-1562. PubMed ID: 35484471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tear Biomarkers in Alzheimer's and Parkinson's Diseases, and Multiple Sclerosis: Implications for Diagnosis (Systematic Review).
    Król-Grzymała A; Sienkiewicz-Szłapka E; Fiedorowicz E; Rozmus D; Cieślińska A; Grzybowski A
    Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alpha-Synuclein in the Gastrointestinal Tract as a Potential Biomarker for Early Detection of Parkinson's Disease.
    Fricova D; Harsanyiova J; Kralova Trancikova A
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33212934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Candidate biomarkers for Parkinson's disease.
    Khodadadian A; Hemmati-Dinarvand M; Kalantary-Charvadeh A; Ghobadi A; Mazaheri M
    Biomed Pharmacother; 2018 Aug; 104():699-704. PubMed ID: 29803930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Salivary Biomarkers for Parkinson's Disease: A Systematic Review with Meta-Analysis.
    Nijakowski K; Owecki W; Jankowski J; Surdacka A
    Cells; 2024 Feb; 13(4):. PubMed ID: 38391952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Updating Our Definitions of Parkinson's Disease for a Molecular Age.
    Chen-Plotkin AS; Zetterberg H
    J Parkinsons Dis; 2018; 8(s1):S53-S57. PubMed ID: 30584165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Membrane interactions of oligomeric alpha-synuclein: potential role in Parkinson's disease.
    van Rooijen BD; Claessens MM; Subramaniam V
    Curr Protein Pept Sci; 2010 Aug; 11(5):334-42. PubMed ID: 20423294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alpha-synuclein in salivary gland as biomarker for Parkinson's disease.
    Campo F; Carletti R; Fusconi M; Pellicano C; Pontieri FE; Di Gioia CR; de Vincentiis M
    Rev Neurosci; 2019 Jul; 30(5):455-462. PubMed ID: 30471223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salivary alpha-synuclein in the diagnosis of Parkinson's disease and Progressive Supranuclear Palsy.
    Vivacqua G; Suppa A; Mancinelli R; Belvisi D; Fabbrini A; Costanzo M; Formica A; Onori P; Fabbrini G; Berardelli A
    Parkinsonism Relat Disord; 2019 Jun; 63():143-148. PubMed ID: 30796010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salivary alpha-synuclein as a biomarker for Parkinson's disease: a systematic review.
    Bougea A; Koros C; Stefanis L
    J Neural Transm (Vienna); 2019 Nov; 126(11):1373-1382. PubMed ID: 31401695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. If not salivary alpha-synuclein, then what? A look at potential Parkinson's disease biomarkers.
    Bougea A
    Expert Rev Mol Diagn; 2020 Apr; 20(4):359-361. PubMed ID: 31986922
    [No Abstract]   [Full Text] [Related]  

  • 18. Nitrated alpha-synuclein in minor salivary gland biopsies in Parkinson's disease.
    Ma LY; Gao LY; Li X; Ma HZ; Feng T
    Neurosci Lett; 2019 Jun; 704():45-49. PubMed ID: 30946930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controlling the mass action of alpha-synuclein in Parkinson's disease.
    Kim C; Lee SJ
    J Neurochem; 2008 Oct; 107(2):303-16. PubMed ID: 18691382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salivary total α-synuclein, oligomeric α-synuclein and SNCA variants in Parkinson's disease patients.
    Kang W; Chen W; Yang Q; Zhang L; Zhang L; Wang X; Dong F; Zhao Y; Chen S; Quinn TJ; Zhang J; Chen S; Liu J
    Sci Rep; 2016 Jun; 6():28143. PubMed ID: 27335051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.